In silico vaccine

  title={In silico vaccine},
  author={Henry Alfred Alford Nicholls},
  journal={Nature Biotechnology},
  • H. Nicholls
  • Published 1 June 2008
  • Medicine
  • Nature Biotechnology
597 David Resnick, a partner at the Bostonbased law firm Nixon Peabody, confirms that with his own story. After his mother died of ovarian cancer, Resnick learned that combined with his ethnic background, that fact meant he had about a 16% chance of having inherited a cancer-related mutation. In part for his young daughter’s sake, he wants to eventually be tested. “But I was waiting for GINA, because I was concerned [the mutation] could be considered a preexisting condition.” Insurers often… 
1 Citations

The bacterial pan-genome and reverse vaccinology.

The whole genome sequence of most human bacterial pathogens is available and the advent of next-generation sequencing technologies will result in a large number of sequenced isolates per pathogenic species, which will help to better inform the reverse vaccinology approach whereby vaccine candidates are identified and prioritized in silico based on genomic data.